Goldman Sachs Upgrades Novo Nordisk A/S (NVO) to Buy
More News related to NVO
- Novo Nordisk is Changing Possibilities in Hemophilia
- New Study Finds Significant Inconsistency With How Diabetes Quality of Care is Measured
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Trading Outlook for Generex Biotechnologies Corp. Issued by InvestorSoup.com
- Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
More News related to Upgrades
- Piper Jaffray Initiates Coverage on UQM Technologies (UQM) with an Overweight; Sees Significant Ramp in Sales Over Next 2-3 Yrs
- Piper Jaffray Initiates Coverage on Clinical Data (CLDA) with an Overweight
- Deutsche Bank Initiates Coverage on Wynn Macau with a Buy
- Consensus Forms That Despite Tremendous YTD Move, Ford (F) Is Still Undervalued
- Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
Goldman Sachs upgrades Novo Nordisk A/S (NYSE: NVO) from Neutral to Buy, saying Levemir to benefit from Lantus safety fears after four studies were published showing the potential of increased cancer risk with Lantus. The firm said the negative press for Lantus will help sales of Novo's Levemir.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products.
Related Categories
UpgradesStocks Mentioned
+1.62Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
